Gritstone Bio Profit Margin 2017-2022 | GRTS
Current and historical gross margin, operating margin and net profit margin for Gritstone Bio (GRTS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Gritstone Bio net profit margin as of June 30, 2022 is -634.23%.
|Gritstone Bio Annual Profit Margins
|Gritstone Bio Quarterly Profit Margins
||Medical - Biomedical and Genetics
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.